{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:16:45Z","timestamp":1762352205139,"version":"3.44.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1053\/j.seminhematol.2012.04.001","type":"journal-article","created":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T05:09:40Z","timestamp":1340168980000},"page":"249-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["General Aspects and Mechanisms of Peripheral Neuropathy Associated With Bortezomib in Patients With Newly Diagnosed Multiple Myeloma"],"prefix":"10.1053","volume":"49","author":[{"given":"Annemiek","family":"Broyl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost L.M.","family":"Jongen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2012.04.001_bib1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jpain.2006.09.014","article-title":"Quantitative sensory findings in patients with bortezomib-induced pain","volume":"8","author":"Cata","year":"2007","journal-title":"J Pain"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1188\/08.CJON.S1.29-35","article-title":"Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board","volume":"12","author":"Tariman","year":"2008","journal-title":"Clin J Oncol Nurs"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib3","first-page":"133","article-title":"The evaluation of peripheral neuropathy","volume":"1","author":"Kelly","year":"2004","journal-title":"Rev Neurol Dis"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","article-title":"Chemotherapy-induced neuropathy","volume":"13","author":"Windebank","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib6","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib7","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib8","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib10","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood.V116.21.40.40","article-title":"HOVON-65\/GMMG-HD4 Randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM)","volume":"116","author":"Sonneveld","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib12","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib13","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib14","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/leu.2010.175","article-title":"Treatment of patients with relapsed\/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies","volume":"24","author":"Dimopoulos","year":"2010","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib15","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib16","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/cncr.22921","article-title":"Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature","volume":"110","author":"Badros","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib17","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/blood.V108.11.3528.3528","article-title":"Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma\u2014efficacy and neurotoxicity","volume":"108","author":"Borrello","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib18","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib19","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199805283382207","article-title":"Neuropathies associated with paraproteinemia","volume":"338","author":"Ropper","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","article-title":"Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study","volume":"86","author":"Dimopoulos","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib21","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib22","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3324\/haematol.2011.041434","article-title":"Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients","volume":"96","author":"Corthals","year":"2011","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib24","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1158\/0008-5472.CAN-04-3684","article-title":"Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341\/bortezomib) cytotoxicity in myeloma cell lines","volume":"65","author":"Landowski","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib25","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1213\/01.ane.0000204318.35194.ed","article-title":"Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy","volume":"102","author":"Siau","year":"2006","journal-title":"Anesth Analg"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib26","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.clinph.2008.08.007","article-title":"Immune-mediated neuropathies in myeloma patients treated with bortezomib","volume":"119","author":"Ravaglia","year":"2008","journal-title":"Clin Neurophysiol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2174\/157489206778776925","article-title":"Bortezomib in the treatment of cancer","volume":"1","author":"Roccaro","year":"2006","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib28","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood.V114.22.3875.3875","article-title":"Pharmacogenomic (PGx) analysis of bortezomib-associated peripheral neuropathy in the phase 3 VISTA trial of bortezomib plus melphalan-prednisone versus melphalan-prednisone in multiple myeloma","volume":"114","author":"Ricci","year":"2009","journal-title":"Blood"},{"year":"2006","series-title":"Common Toxicity Criteria version 2.0 and 3.0","key":"10.1053\/j.seminhematol.2012.04.001_bib29"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/07357909009017560","article-title":"Comprehensive criteria for assessing therapy-induced toxicity","volume":"8","author":"Ajani","year":"1990","journal-title":"Cancer Invest"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"year":"2010","series-title":"Common Toxicity Criteria vesion 4.0","key":"10.1053\/j.seminhematol.2012.04.001_bib34"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib35","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1023\/A:1008344507482","article-title":"Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy","volume":"9","author":"Postma","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","article-title":"The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale","volume":"12","author":"Cavaletti","year":"2007","journal-title":"J Peripher Nerv Syst"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib37","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib38","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib40","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.ejca.2008.04.018","article-title":"Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies","volume":"44","author":"Wolf","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jat.1007","article-title":"Pyridoxine (vitamin B6) neurotoxicity: enhancement by protein-deficient diet","volume":"24","author":"Levine","year":"2004","journal-title":"J Appl Toxicol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib42","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0278-6915(02)00072-8","article-title":"Pyridoxine (vitamin B6) toxicity: enhancement by uremia in rats","volume":"40","author":"Levine","year":"2002","journal-title":"Food Chem Toxicol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1078-0432.CCR-05-2272","article-title":"Velcade and vitamin C: too much of a good thing?","volume":"12","author":"Catley","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib44","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/leu.2009.83","article-title":"Ascorbic acid inhibits antitumor activity of bortezomib in vivo","volume":"23","author":"Perrone","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib45","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1200\/JCO.2008.18.5017","article-title":"From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol","volume":"26","author":"Colvin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2217\/fon.11.42","article-title":"Carfilzomib: a novel second-generation proteasome inhibitor","volume":"7","author":"Khan","year":"2010","journal-title":"Future Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib47","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2007-08-105601","article-title":"Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma","volume":"111","author":"Chauhan","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.001_bib48","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005\u201301 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196312000248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196312000248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:03Z","timestamp":1758522063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196312000248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0037196312000248"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2012.04.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"General Aspects and Mechanisms of Peripheral Neuropathy Associated With Bortezomib in Patients With Newly Diagnosed Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2012.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}